Medicus Pharma meets with lawmakers to support SkinJect designations

Medicus Pharma (MDCX) announced that CEO Raza Bokhari, along with the Medicus leadership team, conducted a series of meetings on Capitol Hill with senior lawmakers across key healthcare committees to advance support for Orphan Drug Designation for SkinJect for Gorlin Syndrome and the rare disease pediatric FDA voucher program. “Our engagement with policymakers reflects a clear alignment around accelerating access to innovative therapies for patients with significant unmet need,” said Raza Bokhari, executive chairman and CEO of Medicus. “We believe SkinJect has the potential to shift the treatment paradigm in Gorlin Syndrome by offering a localized, repeatable, non-surgical approach.”